Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Sodium hydrogen-S-(3-amino-3-hydroxypropyl) phosphorothioate (WR-77913): toxicity and bone marrow radioprotection. [/sup 60/Co]

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
Experiments have been carried out to compare the toxicity and radioprotective effect of sodium hydrogen-S-(3-amino-2-hydroxypropyl) phosphorothioate (WR-77913) with those of S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721). The drugs were given intraperitoneally to 12 week-old female BALB/c mice 30 mintues before whole body irradiation. Lethality at 30 days was the endpoint used. The drug LD/sub 50///sub 30/ was 678 mg/gk for WR-2721 and 3578 mg/kg for Wr-77913. The LD/sub 50///sub 30/ for misonidazole was 380 mg/kg when given in combination with 500 mg/kg of WR-2721 and 801 mg/kg when combined with 2200 mg/kg of WR-77913. Protection of bone marrow by WR-77913 and WR-2721 was comparable at doses close to the maximum tolerable dose (MTD, drug dose lethal to 10% of the animals at 30 days), but WR-77913 gave better protection at 25% of the MTD. These characteristics of low toxicity, non-additive toxicity with WR-2721, less toxicity in combination with misonidazole and adequate bone marrow protection at 25% of the MTD, made WR-77913 a protector worthy of further investigation.
Research Organization:
Univ. of Kentucky Medical Center, Lexington
OSTI ID:
7065926
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 8:3/4; ISSN IOBPD
Country of Publication:
United States
Language:
English